Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics

Virology

Volumn 479-480, Issue , 2015, Pages 331-344

  Pfaller, Christian K ^a   Cattaneo, Roberto ^a   Schnell, Matthias J ^b  

^a MAYO CLINIC   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Attenuation; Cancer therapy; Innate immunity; Mononegavirales; Pathology; Receptors; Reverse genetics; Tropism; Vaccines

Indexed keywords

LIVE VACCINE; VIRUS VACCINE;

GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MONONEGAVIRALES; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PATHOGENICITY; PHYSIOLOGY; PROCEDURES; REVERSE GENETICS; VIRAL TROPISM; VIRUS ASSEMBLY; VIRUS REPLICATION;

HOST-PATHOGEN INTERACTIONS; HUMANS; MONONEGAVIRALES; NEOPLASMS; ONCOLYTIC VIROTHERAPY; REVERSE GENETICS; VACCINES, ATTENUATED; VIRAL TROPISM; VIRAL VACCINES; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 84937511535     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.01.029     Document Type: Review

References (170)

1. Ammayappan A., Kurath G., Thompson T.M., Vakharia V.N. A reverse genetics system for the Great Lakes strain of viral hemorrhagic septicemia virus: the NV gene is required for pathogenicity. Mar. Biotechnol. (NY) 2011, 13:672-683.
2. Barber G.N. VSV-tumor selective replication and protein translation. Oncogene 2005, 24:7710-7719.
3. Barik S., Banerjee A.K. Sequential phosphorylation of the phosphoprotein of vesicular stomatitis virus by cellular and viral protein kinases is essential for transcription activation. J. Virol. 1992, 66:1109-1118.
4. Baron M.D., Barrett T. Rescue of rinderpest virus from cloned cDNA. J. Virol. 1997, 71:1265-1271.
5. Basler C.F., Mikulasova A., Martinez-Sobrido L., Paragas J., Muhlberger E., Bray M., Klenk H.D., Palese P., Garcia-Sastre A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77:7945-7956.
6. Biacchesi S., Skiadopoulos M.H., Tran K.C., Murphy B.R., Collins P.L., Buchholz U.J. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 2004, 321:247-259.
7. Biacchesi S., Thoulouze M.I., Bearzotti M., Yu Y.X., Bremont M. Recovery of NV knockout infectious hematopoietic necrosis virus expressing foreign genes. J. Virol. 2000, 74:11247-11253.
8. Blaney J.E., Marzi A., Willet M., Papaneri A.B., Wirblich C., Feldmann F., Holbrook M., Jahrling P., Feldmann H., Schnell M.J. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathogens 2013, 9:e1003389.
9. Bluming A.Z., Ziegler J.L. Regression of Burkitt[U+05F3]s lymphoma in association with measles infection. Lancet 1971, 2:105-106.
10. Bossert B., Marozin S., Conzelmann K.K. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. J. Virol. 2003, 77:8661-8668.
11. Brzozka K., Finke S., Conzelmann K.K. Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J. Virol. 2005, 79:7673-7681.
12. Brzozka K., Finke S., Conzelmann K.K. Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J. Virol. 2006, 80:2675-2683.
13. Bucheit A.D., Kumar S., Grote D.M., Lin Y., von Messling V., Cattaneo R.B., Fielding A.K. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol. Ther. 2003, 7:62-72.
14. Buchholz U.J., Finke S., Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 1999, 73:251-259.
15. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., Murphy B.R., Collins P.L., Sanchez A. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 2007, 81:6379-6388.
16. Bukreyev A., Skiadopoulos M.H., Murphy B.R., Collins P.L. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 2006, 80:10293-10306.
17. Cardenas W.B., Loo Y.M., Gale M., Hartman A.L., Kimberlin C.R., Martinez-Sobrido L., Saphire E.O., Basler C.F. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 2006, 80:5168-5178.
18. Carnero E., Li W., Borderia A.V., Moltedo B., Moran T., Garcia-Sastre A. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 2009, 83:584-597.
19. Cattaneo R., Miest T., Shashkova E.V., Barry M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 2008, 6:529-540.
20. Cattaneo R., Rebmann G., Schmid A., Baczko K., ter Meulen V., Billeter M.A. Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J. 1987, 6:681-688.
21. Cenna J., Hunter M., Tan G.S., Papaneri A.B., Ribka E.P., Schnell M.J., Marx P.A., McGettigan J.P. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J. Infect. Dis. 2009, 200:1251-1260.
22. Clarke D.K., Sidhu M.S., Johnson J.E., Udem S.A. Rescue of mumps virus from cDNA. J. Virol. 2000, 74:4831-4838.
23. Collins P.L., Bukreyev A., Murphy B.R. What are the risks-hypothetical and observed-of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?. J. Virol. 2008, 82:9805-9806.
24. Collins P.L., Fearns R., Graham B.S. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr. Top. Microbiol. Immunol. 2013, 372:3-38.
25. Collins P.L., Hill M.G., Camargo E., Grosfeld H., Chanock R.M., Murphy B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA 1995, 92:11563-11567.
26. Collins P.L., Mink M.A., Hill M.G., Camargo E., Grosfeld H., Stec D.S. Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA. Virology 1993, 195:252-256.
27. Conzelmann K.K. Reverse genetics of mononegavirales. Curr. Top. Microbiol. Immunol. 2004, 283:1-41.
28. Conzelmann K.K., Schnell M. Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. J. Virol. 1994, 68:713-719.
29. del Valle J.R., Devaux P., Hodge G., Wegner N.J., McChesney M.B., Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J. Virol. 2007, 81:10597-10605.
30. Devaux P., Hodge G., McChesney M.B., Cattaneo R. Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J. Virol. 2008, 82:5359-5367.
31. Devaux P., Hudacek A.W., Hodge G., Reyes-Del Valle J., McChesney M.B., Cattaneo R. A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. J. Virol. 2011, 85:348-356.
32. Devaux P., von Messling V., Songsungthong W., Springfeld C., Cattaneo R. Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 2007, 360:72-83.
33. DiNapoli J.M., Yang L., Samal S.K., Murphy B.R., Collins P.L., Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010, 29:17-25.
34. Dingli D., Peng K.W., Harvey M.E., Greipp P.R., O[U+05F3]Connor M.K., Cattaneo R., Morris J.C., Russell S.J. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103:1641-1646.
35. Edge R.E., Falls T.J., Brown C.W., Lichty B.D., Atkins H., Bell J.C. A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol. Ther. 2008, 16:1437-1443.
36. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
37. Enterlein S., Volchkov V., Weik M., Kolesnikova L., Volchkova V., Klenk H.D., Muhlberger E. Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J. Virol. 2006, 80:1038-1043.
38. Evans J.S., Horton D.L., Easton A.J., Fooks A.R., Banyard A.C. Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine?. Vaccine 2012, 30:7447-7454.
39. Faber M., Faber M.L., Li J., Preuss M.A., Schnell M.J., Dietzschold B. Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. J. Virol. 2007, 81:7041-7047.
40. Faber M., Pulmanausahakul R., Nagao K., Prosniak M., Rice A.B., Koprowski H., Schnell M.J., Dietzschold B. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc. Natl. Acad. Sci. USA 2004, 101:16328-16332.
41. Falsey A.R. Human metapneumovirus infection in adults. Pediatr. Infect. Dis. J. 2008, 27:S80-83.
42. Faul E.J., Aye P.P., Papaneri A.B., Pahar B., McGettigan J.P., Schiro F., Chervoneva I., Montefiori D.C., Lackner A.A., Schnell M.J. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009, 28:299-308.
43. Ferreira C.S., Frenzke M., Leonard V.H., Welstead G.G., Richardson C.D., Cattaneo R. Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). J. Virol. 2010, 84:3033-3042.
44. Fuerst T.R., Earl P.L., Moss B. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol. Cell. Biol. 1987, 7:2538-2544.
45. Galanis E., Hartmann L.C., Cliby W.A., Long H.J., Peethambaram P.P., Barrette B.A., Kaur J.S., Haluska P.J., Aderca I., Zollman P.J., Sloan J.A., Keeney G., Atherton P.J., Podratz K.C., Dowdy S.C., Stanhope C.R., Wilson T.O., Federspiel M.J., Peng K.W., Russell S.J. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010, 70:875-882.
46. Garcin D., Pelet T., Calain P., Roux L., Curran J., Kolakofsky D. A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J. 1995, 14:6087-6094.
47. Gassen U., Collins F.M., Duprex W.P., Rima B.K. Establishment of a rescue system for canine distemper virus. J. Virol. 2000, 74:10737-10744.
48. Gerlier D., Lyles D.S. Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol. Mol. Biol. Rev. 2011, 75:468-490. (second page of table of contents).
49. Ghanem A., Kern A., Conzelmann K.K. Significantly improved rescue of rabies virus from cDNA plasmids. Eur. J. Cell Biol. 2012, 91:10-16.
50. Gomme E.A., Faul E.J., Flomenberg P., McGettigan J.P., Schnell M.J. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol. 2010, 84:2820-2831.
51. Gomme E.A., Wanjalla C.N., Wirblich C., Schnell M.J. Rabies virus as a research tool and viral vaccine vector. Adv. Virus Res. 2011, 79:139-164.
52. Goodbourn S., Randall R.E. The regulation of type I interferon production by paramyxoviruses. J. Interf. Cytokine Res. 2009, 29:539-547.
53. Green T.J., Cox R., Tsao J., Rowse M., Qiu S., Luo M. Common mechanism for RNA encapsidation by negative-strand RNA viruses. J. Virol. 2014, 88:3766-3775.
54. Griffin D.E., Pan C.H. Measles: old vaccines, new vaccines. Curr. Top. Microbiol. Immunol. 2009, 330:191-212.
55. Gupta A.K., Banerjee A.K. Expression and purification of vesicular stomatitis virus N-P complex from Escherichia coli: role in genome RNA transcription and replication in vitro. J. Virol. 1997, 71:4264-4271.
56. Haglund K., Leiner I., Kerksiek K., Buonocore L., Pamer E., Rose J.K. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J. Virol. 2002, 76:7506-7517.
57. Hammond A.L., Plemper R.K., Zhang J., Schneider U., Russell S.J., Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. 2001, 75:2087-2096.
58. Hartman A.L., Bird B.H., Towner J.S., Antoniadou Z.A., Zaki S.R., Nichol S.T. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J. Virol. 2008, 82:2699-2704.
59. He B., Paterson R.G., Ward C.D., Lamb R.A. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 1997, 237:249-260.
60. Herrel M., Haag L., Nilsson J., Staeheli P., Schneider U. Reverse genetics identifies the product of open reading frame 4 as an essential particle assembly factor of Nyamanini virus. J. Virol. 2013, 87:8257-8260.
61. Herrel M., Hoefs N., Staeheli P., Schneider U. Tick-borne Nyamanini virus replicates in the nucleus and exhibits unusual genome and matrix protein properties. J. Virol. 2012, 86:10739-10747.
62. Hoffman M.A., Banerjee A.K. An infectious clone of human parainfluenza virus type 3. J. Virol. 1997, 71:4272-4277.
63. Hudacek A.W., Al-Saleem F.H., Willet M., Eisemann T., Mattis J.A., Simpson L.L., Schnell M.J. Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo. Mol. Ther.-Methods Clin. Dev. 2014, 1.
64. Iverson L.E., Rose J.K. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 1981, 23:477-484.
65. Johnson J.E., Nasar F., Coleman J.W., Price R.E., Javadian A., Draper K., Lee M., Reilly P.A., Clarke D.K., Hendry R.M., Udem S.A. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007, 360:36-49.
66. Johnson M.C., Simon B.E., Kim C.H., Leong J.A. Production of recombinant snakehead rhabdovirus: the NV protein is not required for viral replication. J. Virol. 2000, 74:2343-2350.
67. Kahn J.S., Schnell M.J., Buonocore L., Rose J.K. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 1999, 254:81-91.
68. Karron R.A., Buchholz U.J., Collins P.L. Live-attenuated respiratory syncytial virus vaccines. Curr. Top. Microbiol. Immunol. 2013, 372:259-284.
69. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., Polack F.P., Randolph V.B., Deatly A., Hackell J., Gruber W., Murphy B.R., Collins P.L. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 2005, 191:1093-1104.
70. Kato A., Sakai Y., Shioda T., Kondo T., Nakanishi M., Nagai Y. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1996, 1:569-579. PubMed PMID: 9078386.
71. Kato A., Kiyotani K., Sakai Y., Yoshida T., Nagai Y. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J. 1997, 16:578-587.
72. Katz S.L., John F. Enders and measles virus vaccine-a reminiscence. Curr. Top. Microbiol. Immunol. 2009, 329:3-11.
73. Kawano M., Kaito M., Kozuka Y., Komada H., Noda N., Nanba K., Tsurudome M., Ito M., Nishio M., Ito Y. Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology 2001, 284:99-112.
74. Kelly E., Russell S.J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 2007, 15:651-659.
75. Kelly R.M., Strick P.L. Rabies as a transneuronal tracer of circuits in the central nervous system. J. Neurosci. Methods 2000, 103:63-71.
76. Kinnunen P.M., Palva A., Vaheri A., Vapalahti O. Epidemiology and host spectrum of Borna disease virus infections. J. Gen. Virol. 2013, 94:247-262.
77. Kinoh H., Inoue M., Washizawa K., Yamamoto T., Fujikawa S., Tokusumi Y., Iida A., Nagai Y., Hasegawa M. Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Ther. 2004, 11:1137-1145.
78. Kormelink R., Garcia M.L., Goodin M., Sasaya T., Haenni A.L. Negative-strand RNA viruses: the plant-infecting counterparts. Virus Res. 2011, 162:184-202.
79. Kuhn J.H., Bao Y., Bavari S., Becker S., Bradfute S., Brauburger K., Rodney Brister J., Bukreyev A.A., Cai Y., Chandran K., Davey R.A., Dolnik O., Dye J.M., Enterlein S., Gonzalez J.P., Formenty P., Freiberg A.N., Hensley L.E., Hoenen T., Honko A.N., Ignatyev G.M., Jahrling P.B., Johnson K.M., Klenk H.D., Kobinger G., Lackemeyer M.G., Leroy E.M., Lever M.S., Muhlberger E., Netesov S.V., Olinger G.G., Palacios G., Patterson J.L., Paweska J.T., Pitt L., Radoshitzky S.R., Ryabchikova E.I., Saphire E.O., Shestopalov A.M., Smither S.J., Sullivan N.J., Swanepoel R., Takada A., Towner J.S., van der Groen G., Volchkov V.E., Volchkova V.A., Wahl-Jensen V., Warren T.K., Warfield K.L., Weidmann M., Nichol S.T. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch. Virol. 2014, 159:1229-1237.
80. Kurisetty V.V., Heiber J., Myers R., Pereira G.S., Goodwin J.W., Federspiel M.J., Russell S.J., Peng K.W., Barber G., Merchan J.R. Preclinical safety and activity of recombinant VSV-IFN-beta in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck 2014, 36:1619-1627.
81. Kurup D., Wirblich C., Feldmann H., Marzi A., Schnell M.J. Rhabdoviral-based vaccine platforms against Henipaviruses. J. Virol. 2014.
82. Lamb R.A., Parks G.D. Paramyxoviridae. Fields Virology 2013, 6:957-995. Lippincott Williams & Wilkins, Philadelphia. revised ed.
83. Lauring A.S., Frydman J., Andino R. The role of mutational robustness in RNA virus evolution. Nat. Rev. Microbiol. 2013, 11:327-336.
84. Lawrence T.M., Wanjalla C.N., Gomme E.A., Wirblich C., Gatt A., Carnero E., Garcia-Sastre A., Lyles D.S., McGettigan J.P., Schnell M.J. Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses. PLoS One 2013, 8:e67123.
85. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 1995, 92:4477-4481.
86. Le Mercier P., Jacob Y., Tanner K., Tordo N. A novel expression cassette of lyssavirus shows that the distantly related Mokola virus can rescue a defective rabies virus genome. J. Virol. 2002, 76:2024-2027.
87. Le Nouen C., Brock L.G., Luongo C., McCarty T., Yang L., Mehedi M., Wimmer E., Mueller S., Collins P.L., Buchholz U.J., DiNapoli J.M. Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization. Proc. Natl. Acad. Sci. USA 2014, 111:13169-13174.
88. Leber M.F., Bossow S., Leonard V.H., Zaoui K., Grossardt C., Frenzke M., Miest T., Sawall S., Cattaneo R., von Kalle C., Ungerechts G. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol. Ther. 2011, 19:1097-1106.
89. Lemon K., de Vries R.D., Mesman A.W., McQuaid S., van Amerongen G., Yuksel S., Ludlow M., Rennick L.J., Kuiken T., Rima B.K., Geijtenbeek T.B., Osterhaus A.D., Duprex W.P., de Swart R.L. Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathogens 2011, 7:e1001263.
90. Leonard V.H., Hodge G., Reyes-Del Valle J., McChesney M.B., Cattaneo R. Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J. Virol. 2010, 84:3413-3420.
91. Leonard V.H., Sinn P.L., Hodge G., Miest T., Devaux P., Oezguen N., Braun W., McCray P.B., McChesney M.B., Cattaneo R. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J. Clin. Investig. 2008, 118:2448-2458.
92. Letunic I., Bork P. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics 2007, 23:127-128.
93. Letunic I., Bork P. Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. Nucl. Acids Res. 2011, 39:W475-W478.
94. Liu T.C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 2007, 4:101-117.
95. Lo M.S., Brazas R.M., Holtzman M.J. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J. Virol. 2005, 79:9315-9319.
96. Lorin C., Mollet L., Delebecque F., Combredet C., Hurtrel B., Charneau P., Brahic M., Tangy F. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 2004, 78:146-157.
97. Luongo C., Winter C.C., Collins P.L., Buchholz U.J. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J. Virol. 2013, 87:1985-1996.
98. Luytjes W., Krystal M., Enami M., Parvin J.D., Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 1989, 59:1107-1113.
99. Marschalek A., Finke S., Schwemmle M., Mayer D., Heimrich B., Stitz L., Conzelmann K.K. Attenuation of rabies virus replication and virulence by picornavirus internal ribosome entry site elements. J. Virol. 2009, 83:1911-1919.
100. Marsh G.A., Virtue E.R., Smith I., Todd S., Arkinstall R., Frazer L., Monaghan P., Smith G.A., Broder C.C., Middleton D., Wang L.F. Recombinant Hendra viruses expressing a reporter gene retain pathogenicity in ferrets. Virol. J. 2013, 10:95.
101. Marzi A., Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev. Vaccines 2014, 13:521-531.
102. Mateo M., Navaratnarajah C.K., Cattaneo R. Structural basis of efficient contagion: measles variations on a theme by parainfluenza viruses. Curr. Opin. Virol. 2014, 5:16-23.
103. McGettigan J.P., David F., Figueiredo M.D., Minke J., Mebatsion T., Schnell M.J. Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs. Vaccine 2014, 32:1716-1719.
104. McGettigan J.P., Naper K., Orenstein J., Koser M., McKenna P.M., Schnell M.J. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J. Virol. 2003, 77:10889-10899.
105. McKenna P.M., Aye P.P., Dietzschold B., Montefiori D.C., Martin L.N., Marx P.A., Pomerantz R.J., Lackner A., Schnell M.J. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J. Virol. 2004, 78:13455-13459.
106. Mebatsion T., Schnell M.J., Cox J.H., Finke S., Conzelmann K.K. Highly stable expression of a foreign gene from rabies virus vectors. Proc. Natl. Acad. Sci. USA 1996, 93:7310-7314.
107. Meng J., Lee S., Hotard A.L., Moore M.L. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. MBio 2014, 5:e01704-01714.
108. Miest T.S., Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat. Rev. Microbiol. 2014, 12:23-34.
109. Miest T.S., Frenzke M., Cattaneo R. Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy. Mol. Ther. 2013, 21:2019-2031.
110. Mihindukulasuriya K.A., Nguyen N.L., Wu G., Huang H.V., da Rosa A.P., Popov V.L., Tesh R.B., Wang D. Nyamanini and midway viruses define a novel taxon of RNA viruses in the order Mononegavirales. J. Virol. 2009, 83:5109-5116.
111. Mrkic B., Pavlovic J., Rulicke T., Volpe P., Buchholz C.J., Hourcade D., Atkinson J.P., Aguzzi A., Cattaneo R. Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 1998, 72:7420-7427.
112. Muhlebach M.D., Mateo M., Sinn P.L., Prufer S., Uhlig K.M., Leonard V.H., Navaratnarajah C.K., Frenzke M., Wong X.X., Sawatsky B., Ramachandran S., McCray P.B., Cichutek K., von Messling V., Lopez M., Cattaneo R. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011, 480:530-533.
113. Myers R.M., Greiner S.M., Harvey M.E., Griesmann G., Kuffel M.J., Buhrow S.A., Reid J.M., Federspiel M., Ames M.M., Dingli D., Schweikart K., Welch A., Dispenzieri A., Peng K.W., Russell S.J. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin. Pharmacol. Ther. 2007, 82:700-710.
114. Nakamura T., Peng K.W., Harvey M., Greiner S., Lorimer I.A., James C.D., Russell S.J. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 2005, 23:209-214.
115. Newman J.T., Surman S.R., Riggs J.M., Hansen C.T., Collins P.L., Murphy B.R., Skiadopoulos M.H. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 2002, 24:77-92.
116. Obuchi M., Fernandez M., Barber G.N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 2003, 77:8843-8856.
117. Ottolino-Perry K., Diallo J.S., Lichty B.D., Bell J.C., McCart J.A. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 2010, 18:251-263.
118. Papaneri A.B., Wirblich C., Cooper K., Jahrling P.B., Schnell M.J., Blaney J.E. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine 2012, 30:6136-6141.
119. Park K.H., Huang T., Correia F.F., Krystal M. Rescue of a foreign gene by Sendai virus. Proc. Natl. Acad. Sci. USA 1991, 88:5537-5541.
120. Parks G.D., Alexander-Miller M.A. Paramyxovirus activation and inhibition of innate immune responses. J. Mol. Biol. 2013, 425:4872-4892.
121. Pattnaik A.K., Ball L.A., LeGrone A.W., Wertz G.W. Infectious defective interfering particles of VSV from transcripts of a cDNA clone. Cell 1992, 69:1011-1020.
122. Peng K.W., Facteau S., Wegman T., O[U+05F3]Kane D., Russell S.J. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 2002, 8:527-531.
123. Peng K.W., Frenzke M., Myers R., Soeffker D., Harvey M., Greiner S., Galanis E., Cattaneo R., Federspiel M.J., Russell S.J. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum. Gene Ther. 2003, 14:1565-1577.
124. Peng K.W., Hadac E.M., Anderson B.D., Myers R., Harvey M., Greiner S.M., Soeffker D., Federspiel M.J., Russell S.J. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther. 2006, 13:732-738.
125. Publicover J., Ramsburg E., Rose J.K. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J. Virol. 2004, 78:9317-9324.
126. Pulmanausahakul R., Li J., Schnell M.J., Dietzschold B. The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. J. Virol. 2008, 82:2330-2338.
127. Racaniello V.R., Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc. Natl. Acad. Sci. USA 1981, 78:4887-4891.
128. Radecke F., Spielhofer P., Schneider H., Kaelin K., Huber M., Dotsch C., Christiansen G., Billeter M.A. Rescue of measles viruses from cloned DNA. EMBO J. 1995, 14:5773-5784.
129. Ramachandran A., Horvath C.M. Paramyxovirus disruption of interferon signal transduction: STATus report. J. Interf. Cytokine Res. 2009, 29:531-537.
130. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., Montefiori D., Earl P., Moss B., Rose J.K. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J. Virol. 2004, 78:3930-3940.
131. Reid S.P., Leung L.W., Hartman A.L., Martinez O., Shaw M.L., Carbonnelle C., Volchkov V.E., Nichol S.T., Basler C.F. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 2006, 80:5156-5167.
132. Reuter J.D., Vivas-Gonzalez B.E., Gomez D., Wilson J.H., Brandsma J.L., Greenstone H.L., Rose J.K., Roberts A. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J. Virol. 2002, 76:8900-8909.
133. Rieder M., Brzozka K., Pfaller C.K., Cox J.H., Stitz L., Conzelmann K.K. Genetic dissection of interferon-antagonistic functions of rabies virus phosphoprotein: inhibition of interferon regulatory factor 3 activation is important for pathogenicity. J. Virol. 2011, 85:842-852.
134. Rieder M., Conzelmann K.K. Rhabdovirus evasion of the interferon system. J. Interf. Cytokine Res. 2009, 29:499-509.
135. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., Kawaoka Y., Rose J.K. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 1998, 72:4704-4711.
136. Romer-Oberdorfer A., Mundt E., Mebatsion T., Buchholz U.J., Mettenleiter T.C. Generation of recombinant lentogenic Newcastle disease virus from cDNA. J. Gen. Virol. 1999, 80(Pt 11):2987-2995.
137. Russell S.J., Federspiel M.J., Peng K.W., Tong C., Dingli D., Morice W.G., Lowe V., O[U+05F3]Connor M.K., Kyle R.A., Leung N., Buadi F.K., Rajkumar S.V., Gertz M.A., Lacy M.Q., Dispenzieri A. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin. Proc. 2014, 89:926-933.
138. Russell S.J., Peng K.W. Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol. 2009, 330:213-241.
139. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30:658-670.
140. Schmidt A.C., McAuliffe J.M., Huang A., Surman S.R., Bailly J.E., Elkins W.R., Collins P.L., Murphy B.R., Skiadopoulos M.H. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J. Virol. 2000, 74:8922-8929.
141. Schneider-Schaulies S., Schneider-Schaulies J. Measles virus-induced immunosuppression. Curr. Top. Microbiol. Immunol. 2009, 330:243-269.
142. Schneider U., Bullough F., Vongpunsawad S., Russell S.J., Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J. Virol. 2000, 74:9928-9936.
143. Schneider U., Schwemmle M., Staeheli P. Genome trimming: a unique strategy for replication control employed by Borna disease virus. Proc. Natl. Acad. Sci. USA 2005, 102:3441-3446.
144. Schneider W.M., Chevillotte M.D., Rice C.M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 2014, 32:513-545.
145. Schnell M.J., Buonocore L., Whitt M.A., Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 1996, 70:2318-2323.
146. Schnell M.J., Mebatsion T., Conzelmann K.K. Infectious rabies viruses from cloned cDNA. EMBO J. 1994, 13:4195-4203.
147. Sinn P.L., Williams G., Vongpunsawad S., Cattaneo R., McCray P.B. Measles virus preferentially transduces the basolateral surface of well-differentiated human airway epithelia. J. Virol. 2002, 76:2403-2409.
148. Spann K.M., Collins P.L., Teng M.N. Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J. Virol. 2003, 77:11201-11211.
149. Spann K.M., Tran K.C., Collins P.L. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J. Virol. 2005, 79:5353-5362.
150. Springfeld C., von Messling V., Frenzke M., Ungerechts G., Buchholz C.J., Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res. 2006, 66:7694-7700.
151. Svitek N., Gerhauser I., Goncalves C., Grabski E., Doring M., Kalinke U., Anderson D.E., Cattaneo R., von Messling V. Morbillivirus control of the interferon response: relevance of STAT2 and mda5 but not STAT1 for canine distemper virus virulence in ferrets. J. Virol. 2014, 88:2941-2950.
152. Taniguchi T., Palmieri M., Weissmann C. QB DNA-containing hybrid plasmids giving rise to QB phage formation in the bacterial host. Nature 1978, 274:223-228.
153. Tatsuo H., Ono N., Tanaka K., Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000, 406:893-897.
154. Taxonomy, V., 2013. Virus Taxonomy: 2013 Release, Edinburgh.
155. Ungerechts G., Frenzke M.E., Yaiw K.C., Miest T., Johnston P.B., Cattaneo R. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther. 2010, 17:1506-1516.
156. Ungerechts G., Springfeld C., Frenzke M.E., Lampe J., Johnston P.B., Parker W.B., Sorscher E.J., Cattaneo R. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res. 2007, 67:10939-10947.
157. Valmas C., Grosch M.N., Schumann M., Olejnik J., Martinez O., Best S.M., Krahling V., Basler C.F., Muhlberger E. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathogens 2010, 6:e1000721.
158. Vidy A., Chelbi-Alix M., Blondel D. Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J. Virol. 2005, 79:14411-14420.
159. Volchkov V.E., Volchkova V.A., Muhlberger E., Kolesnikova L.V., Weik M., Dolnik O., Klenk H.D. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001, 291:1965-1969.
160. von Messling V., Milosevic D., Cattaneo R. Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc. Natl. Acad. Sci. USA 2004, 101:14216-14221.
161. von Messling V., Svitek N., Cattaneo R. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J. Virol. 2006, 80:6084-6092.
162. Vos A., Conzelmann K.K., Finke S., Muller T., Teifke J., Fooks A.R., Neubert A. Immunogenicity studies in carnivores using a rabies virus construct with a site-directed deletion in the phosphoprotein. Adv. Prev. Med. 2011, 2011:898171.
163. Wertz G.W., Perepelitsa V.P., Ball L.A. Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc. Natl. Acad. Sci. USA 1998, 95:3501-3506.
164. Whelan S.P., Ball L.A., Barr J.N., Wertz G.T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. USA 1995, 92:8388-8392.
165. Whelan S.P., Barr J.N., Wertz G.W. Transcription and replication of nonsegmented negative-strand RNA viruses. Curr. Top. Microbiol. Immunol. 2004, 283:61-119.
166. Wickersham I.R., Sullivan H.A., Seung H.S. Axonal and subcellular labelling using modified rabies viral vectors. Nat. Commun. 2013, 4:2332.
167. Willmon C.L., Saloura V., Fridlender Z.G., Wongthida P., Diaz R.M., Thompson J., Kottke T., Federspiel M., Barber G., Albelda S.M., Vile R.G. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 2009, 69:7713-7720.
168. Wiltzer L., Okada K., Yamaoka S., Larrous F., Kuusisto H.V., Sugiyama M., Blondel D., Bourhy H., Jans D.A., Ito N., Moseley G.W. Interaction of rabies virus P-protein with STAT proteins is critical to lethal rabies disease. J. Infect. Dis. 2014, 209:1744-1753.
169. Yoneda M., Guillaume V., Ikeda F., Sakuma Y., Sato H., Wild T.F., Kai C. Establishment of a Nipah virus rescue system. Proc. Natl. Acad. Sci. USA 2006, 103:16508-16513.
170. Yun T., Park A., Hill T.E., Pernet O., Beaty S.M., Juelich T.L., Smith J.K., Zhang L., Wang Y.E., Vigant F., Gao J., Wu P., Lee B., Freiberg A.N. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra virus and enables real-time monitoring of viral spread in small animal models of henipavirus infection. J. Virol. 2014.